Abaloparatide vs Ipamorelin
Extensively Studied vs Well Studied
synergistic Mechanism-based · 47% Abaloparatide and Ipamorelin work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
Abaloparatide Ipamorelin
Weight 3,960 Da 711.85 Da
Half-life ~1.7 hours ~2 hours
Chain 34 amino acids 5 amino acids
Type Synthetic PTHrP analog Growth hormone secretagogue
Key Benefits
Abaloparatide
01 FDA-approved for osteoporosis treatment
02 Actively builds new bone (anabolic mechanism)
03 Superior hip BMD gains vs teriparatide in trials
04 Reduces vertebral fracture risk significantly
05 Reduces nonvertebral fracture risk
06 Lower hypercalcemia risk than teriparatide
07 Works through selective PTH1R activation
08 Benefits seen within 6 months
Ipamorelin
01 Optimal GH stimulation with superior bioavailability
02 Body composition improvements (lean mass, fat loss)
03 Enhanced recovery and anti-aging effects
04 Minimal side effects compared to other GHRPs
05 No significant cortisol or prolactin elevation
06 Improved sleep quality
Dosing Protocols
Abaloparatide
80 mcg / Once daily
Osteoporosis treatment 80 mcg Once daily
Ipamorelin
200-300 mcg per injection / 1-3 times daily depending on goals (1x for longevity, 2-3x for performance)
General Health & Longevity 200mcg 1x daily before bed
Body Composition 250-300mcg 2x daily (morning, pre-workout)
Athletic Performance 200-250mcg 2-3x daily
Sleep & Recovery 200mcg 1x daily 30min before bed
Anti-Aging Protocol 200-250mcg 1-2x daily
Side Effects
Abaloparatide
Hypercalciuria (high calcium in urine)
Dizziness
Nausea
Headache
Palpitations
Fatigue
Upper abdominal pain
Vertigo
Injection site reactions
Ipamorelin
Mild hunger increase 20-30 minutes post-injection
Slight drowsiness when taken before bed
Water retention (mild)
Contraindications
Paget's disease of bone
Prior external beam or implant radiation therapy to skeleton
Bone metastases or history of skeletal malignancies
Metabolic bone diseases other than osteoporosis
Pre-existing hypercalcemia
Pregnancy or nursing
Cumulative use exceeding 2 years lifetime
Pregnancy or breastfeeding
Active cancer or history of cancer
Severe kidney or liver disease
Research Evidence
Abaloparatide Ipamorelin
Status Extensively Studied Well Studied
References 4 studies 5 studies
Latest — October 2024
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.